CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 91 enrolled
Drug / intervention
E2007drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03201900
NCT03201900Phase 3Completed

A Multicenter, Uncontrolled, Open-label Study and Extension Study for Verification of Eefficacy and Safety for Perampanel Monotherapy in Untreated Patients With Partial Onset Seizures (Including Secondarily Generalized Seizures) (FREEDOM Study)

Eisai Co., Ltd.·interventional·Posted Jun 28, 2017·Updated Aug 5, 2021

In Brief

A Phase 3 clinical trial evaluating E2007 for Partial Onset Seizures. Completed, enrolled 91 participants across 38 sites in 2 countries.

Detailed Summary

This study is conducted to evaluate the seizure-free rate of the 26-week Maintenance Period in untreated participants with partial onset seizures (POS).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesJapan, South Korea
Collaborators--

Timeline

Phase 3CompletedFinished
201820192020202120222023202420252026
First PostedJun 28, 2017
Enrollment StartJun 28, 2017
Primary CompletionFeb 28, 2019
Study CompletionJul 27, 2020
TodayJul 2, 2026
Enrollment to primary: 1.7 yearsPosted 9.0 years ago

Interventions

E2007drug

Oral tablet